Vetoquinol SA (EPA:VETO)

Market Cap	841.44M -2.1%
Revenue (ttm)	525.69M -2.5%
Net Income	57.36M -2.3%
EPS	4.94 -0.8%
Shares Out	11.62M
PE Ratio	14.67
Forward PE	14.59
Dividend	0.93 (1.31%)
Ex-Dividend Date	Jun 3, 2026

Volume	5,136
Open	70.70
Previous Close	70.80
Day's Range	70.20 - 72.40
52-Week Range	67.20 - 91.50
Beta	0.89
Analysts	Buy
Price Target	90.38 (+24.83%)
Earnings Date	Sep 11, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,486
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2025, Vetoquinol's revenue was 525.69 million, a decrease of -2.51% compared to the previous year's 539.20 million. Earnings were 57.36 million, a decrease of -2.26%.

Analyst Summary

According to 4 analysts, the average rating for VETO stock is "Buy." The 12-month stock price target is €90.38, which is an increase of 24.83% from the latest price.

Price Target

€90.38

(24.83% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 23, 2026

Data Sources Report a data error